PRCT NASDAQ
Credit Risk of going bust: lower than 56% of companies Debt: 6.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.12 (down 99.4%), PROCEPT BioRobotics Corporation would be worth roughly what it owes.
Total debt $77.5M against a stock market value of $1.13B.
Distance to default 5.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $25.9M (short-term plus half of long-term), stock volatility 65.2%; Altman Z 3.68. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Jose, CA 95134
US
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majorityâ78 unitsâlocated in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mack Michael | A-Award | 7,727 | — | 2026-10-02 |
| Mack Michael | A-Award | 12,191 | $17.16 | 2026-10-02 |
| Mack Michael | 0 | — | 2026-10-02 | |
| Nouri Alaleh | S-Sale | 297 | $20.95 | 2026-09-09 |
| Templin Barry L | S-Sale | 373 | $20.95 | 2026-09-09 |